Enteric-coated mycophenolate sodium: Safe conversion from mycophenolate mofetil in maintenance renal transplant recipients

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S524-S527

  Budde, K ^a,b   Glander, P ^a   Diekmann, F ^a   Dragun, D ^a   Waiser, J ^a   Fritsche, L ^a   Neumayer, H H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COST OF ILLNESS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENTERIC COATED TABLET; GASTROINTESTINAL DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; NEUTROPENIA; PRIORITY JOURNAL; RECIPIENT;

EID: 1642342861     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.12.042     Document Type: Article

References (18)

1. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 345:1995;1321.
2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 61:1996;1029.
3. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 60:1995;225.
4. Takemoto SK: In Cecka JM, Terasaki PI (eds): 16th Annual Volume Clinical Transplantations. Los Angeles, Calif.: UCLA Immunogenetics Center; 2000, p 481.
5. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 69:2000;2405.
6. Meier-Kriesche H.U., Ojo A.O., Leichtman A.B., et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol. 11:2000;2366.
7. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Aetiology, incidence and management. Drug Safety. 24:2001;645.
8. Hale M.D., Nicholls A.J., Bullingham R.E., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 64:1998;672.
9. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant. 17:2003;200.
10. Hardinger L.K., Brennan D.C., Mutinga N., et al. Graft survival and cost following gastrointestinal complications in renal transplant recipients treated with mycophenolate mofetil. Am J Transplant. 3:(suppl 5):2003;56.
11. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 14:2003;2381.
12. Ferguson RM, Porterfield-Baxa J, Tierce JC, et al: The cost of mycophenolate mofetil-related (MMF) gastrointestinal adverse events and impact of MMF dose-reductions/discontinuations on acute rejection in transplanted patients. European Society for Organ Transplantation, Venice, Italy, 20-24 September 2003 (Abstract 707).
13. Bjarnason I. Enteric coating of mycophenolate sodium A rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc. 33:2001;3238.
14. Schmouder R, Arns W, Merkel F, et al: Pharmacokinetics of ERL080A: a new enteric coated formulation of mycophenolic acid-sodium. 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, USA, 15-19 May, 1999 (Abstract 787).
15. Budde K., Glander P., Hahn U., et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance renal transplant patients. Am J Transplant. 2:(suppl 3):2002;399.
16. Budde K., Curtis J., Knoll G., et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients results of a 1-year study. Am J Transplant. 4:2004;237.
17. Granger D.K. Enteric-coated mycophenolate sodium Results of two pivotal global multicenter trials. Transplant Proc. 33:2001;3241.
18. Neumayer H-H, Curtis J, Panis C, et al: Tolerability and safety of enteric-coated mycophenolate sodium (EC-MPS) versus MMF in maintenance renal transplant patients. '2001 A Transplant Odyssey - The Future is Here', Istanbul, Turkey, 20-23 August, 2001 (Abstract 1800).